Jab ends scaly skin misery for 60% of psoriasis patients


Sumary of Jab ends scaly skin misery for 60% of psoriasis patients:

  • Professor Richard Warren, consultant dermatologist at Salford Royal NHS Foundation Trust and lead investigator on the bimekizumab trial, says that life for those worst affected can be unbearable..
  • Bimekizumab is the first treatment of its kind to target specific immune-system proteins – called Interleukin 17A and Interleukin 17F..
  • Astonishingly, by week 16, more than 60 per cent reached ‘complete skin clearance’, meaning they had no patches anywhere on the body….

Want to know more click here go to source.

From -
Generic selectors
Exact matches only
Search in title
Search in content

Site Language

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.